Celldex Therapeutics

New Capabilities

As of September 2026: Developer of barzolvolimab; plans BLA submission in 2027

Celldex's experimental antibody barzolvolimab beat placebo in two Phase 3 trials for chronic spontaneous urticaria, the condition behind recurring hives and severe itching. Roughly 42% to 46% of treated patients were completely symptom-free at 12 weeks, versus about 10% on placebo. The drug works by depleting the mast cells that drive the disease—a mechanism no approved CSU therapy uses.

Updated Sep 22